Switch theme
Sign up to access all valuation multiples
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
2012
21
Last FY Revenue n/a
LTM EBITDA -$21.8M
$51.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Immix Biopharma has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$21.8M.
In the most recent fiscal year, Immix Biopharma achieved revenue of n/a and an EBITDA of -$22.6M.
Immix Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Immix Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$21.8M | XXX | -$22.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$21.9M | XXX | -$22.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$20.9M | XXX | -$21.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Immix Biopharma's stock price is $2.
Immix Biopharma has current market cap of $66.3M, and EV of $51.5M.
See Immix Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $51.5M | $66.3M | XXX | XXX | XXX | XXX | $-0.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Immix Biopharma has market cap of $66.3M and EV of $51.5M.
Immix Biopharma's trades at n/a EV/Revenue multiple, and -2.3x EV/EBITDA.
Equity research analysts estimate Immix Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immix Biopharma has a P/E ratio of -3.2x.
See valuation multiples for Immix Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $66.3M | XXX | $66.3M | XXX | XXX | XXX |
| EV (current) | $51.5M | XXX | $51.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.4x | XXX | -2.3x | XXX | XXX | XXX |
| EV/EBIT | -2.3x | XXX | -2.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.2x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmix Biopharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Immix Biopharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Immix Biopharma's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Immix Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immix Biopharma acquired XXX companies to date.
Last acquisition by Immix Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Immix Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Immix Biopharma founded? | Immix Biopharma was founded in 2012. |
| Where is Immix Biopharma headquartered? | Immix Biopharma is headquartered in United States of America. |
| How many employees does Immix Biopharma have? | As of today, Immix Biopharma has 21 employees. |
| Who is the CEO of Immix Biopharma? | Immix Biopharma's CEO is Dr. Ilya Rachman. |
| Is Immix Biopharma publicy listed? | Yes, Immix Biopharma is a public company listed on NAS. |
| What is the stock symbol of Immix Biopharma? | Immix Biopharma trades under IMMX ticker. |
| When did Immix Biopharma go public? | Immix Biopharma went public in 2021. |
| Who are competitors of Immix Biopharma? | Similar companies to Immix Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Immix Biopharma? | Immix Biopharma's current market cap is $66.3M |
| Is Immix Biopharma profitable? | Yes, Immix Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Immix Biopharma? | Immix Biopharma's last 12 months EBITDA is -$21.8M. |
| What is the current EV/EBITDA multiple of Immix Biopharma? | Current EBITDA multiple of Immix Biopharma is -2.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
